Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.

Hemoglobin - 1 Jan 2012

Banan Mehdi, Bayat Hadi, Azarkeivan Azita, Mohammadparast Saeid, Kamali Koorosh, Farashi Samaneh, Bayat Nooshin, Khani Masumeh Hadavand, Neishabury Maryam, Najmabadi Hossein

Abstract excerpt

Hydroxyurea (HU), a drug which can reactivate fetal hemoglobin (Hb F) production, is frequently prescribed to β-thalassemia (β-thal) patients. However, transfusion requirements of only a subset of patients are reduced upon HU treatment. Because of its potential side-effects, targeted prescription of HU is imperative. To identify genetic markers that correlate with drug response, we have carried out a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Thalassemia
Share to Blood Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Hemoglobin

Share to Hydroxyurea

Share to Prognosis

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 22686296
DOI: 10.3109/03630269.2012.691147

Genes

MYB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.PMID 22686296Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.Semantic proximity Read ↗

Single Nucleotide Polymorphisms in XMN1-HBG2, HBS1L-MYB, and BCL11A and Their Relation to High Fetal Hemoglobin Levels That Alleviate AnemiaSemantic proximity Read ↗

The Impact of XmnI-HBG2, BCL11A and HBS1L-MYB Single Nucleotide Polymorphisms on Hb F Variation of Hematologically Normal Iranian Individuals.Semantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.Semantic proximity Read ↗

Pharmacogenomics and therapeutics of hemoglobinopathies.Semantic proximity Read ↗

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.Semantic proximity Read ↗

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.Semantic proximity Read ↗

Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical ApplicationsSemantic proximity Read ↗

The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.Semantic proximity Read ↗

Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.